Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04762979 |
|---|---|
| Brief Title: | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
| First Submitted : | February 17, 2021 |
| First Submitted that Met QC Criteria : | February 17, 2021 |
| First Posted : | February 21, 2021 |
| Last Update Submitted that Met QC Criteria : | March 17, 2023 |
| Last Update Posted : | March 20, 2023 |